Maged Shenouda Relmada Therapeutics, Inc. (RLMD) insider trading activity

Maged Shenouda is Chief Financial Officer of RELMADA THERAPEUTICS, INC.. Currently has a direct ownership of 288,335 shares of RLMD, which is worth approximately $204,717. The most recent transaction as insider was on May 20, 2025, when has been sold 60,000 shares (Common Stock) at a price of $0.52 per share, resulting in proceeds of $31,200. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 288K

226.41% 3M change

726.1% 12M change

Total Value Held $204,717

Maged Shenouda Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 20 2025	BUY Open market or private purchase	$31,200 $0.52 p/Share	60,000 Added 17.22%	288,335 Common Stock
May 19 2025	BUY Open market or private purchase	$44,100 $0.49 p/Share	90,000 Added 28.27%	228,335 Common Stock
May 16 2025	BUY Open market or private purchase	$22,000 $0.44 p/Share	50,000 Added 26.55%	138,335 Common Stock
Sep 11 2024	BUY Open market or private purchase	$71,154 $2.95 p/Share	24,120 Added 21.45%	88,335 Common Stock
Sep 10 2024	BUY Open market or private purchase	$57,652 $2.73 p/Share	21,118 Added 24.75%	64,215 Common Stock
Sep 09 2024	BUY Open market or private purchase	$20,894 $2.55 p/Share	8,194 Added 15.98%	43,097 Common Stock
Jan 31 2024	BUY Open market or private purchase	$27,912 $4.06 p/Share	6,875 Added 16.46%	34,903 Common Stock
Jan 30 2024	BUY Open market or private purchase	$58,350 $3.89 p/Share	15,000 Added 34.86%	28,028 Common Stock
Jan 29 2024	BUY Open market or private purchase	$39,420 $3.65 p/Share	10,800 Added 45.32%	13,028 Common Stock
Mar 10 2021	SELL Open market or private sale	$83,316 $35.11 p/Share	2,373 Reduced 51.58%	2,228 Common Stock
Mar 09 2021	SELL Open market or private sale	$268,864 $35.72 p/Share	7,527 Reduced 62.06%	4,601 Common Stock
Mar 08 2021	SELL Open market or private sale	$3,500 $35.0 p/Share	100 Reduced 0.82%	12,128 Common Stock
Mar 08 2021	BUY Exercise of conversion of derivative security	$32,400 $3.24 p/Share	10,000 Added 44.99%	12,228 Common Stock
Feb 24 2021	SELL Open market or private sale	$102,630 $34.21 p/Share	3,000 Reduced 57.38%	2,228 Common Stock
Feb 24 2021	BUY Exercise of conversion of derivative security	$9,720 $3.24 p/Share	3,000 Added 36.46%	5,228 Common Stock
Feb 11 2021	SELL Open market or private sale	$50,537 $35.39 p/Share	1,428 Reduced 39.06%	2,228 Common Stock
Feb 11 2021	BUY Exercise of conversion of derivative security	$4,627 $3.24 p/Share	1,428 Added 28.09%	3,656 Common Stock
Feb 10 2021	SELL Open market or private sale	$84,832 $35.2 p/Share	2,410 Reduced 51.96%	2,228 Common Stock
Feb 09 2021	SELL Open market or private sale	$188,851 $35.24 p/Share	5,359 Reduced 53.61%	4,638 Common Stock
Feb 08 2021	SELL Open market or private sale	$126,249 $35.04 p/Share	3,603 Reduced 26.49%	9,997 Common Stock
Feb 08 2021	BUY Exercise of conversion of derivative security	$36,845 $3.24 p/Share	11,372 Added 45.54%	13,600 Common Stock
Feb 03 2021	SELL Open market or private sale	$3,500 $35.0 p/Share	100 Reduced 4.3%	2,228 Common Stock
Feb 02 2021	SELL Open market or private sale	$108,624 $35.04 p/Share	3,100 Reduced 57.11%	2,328 Common Stock
Feb 02 2021	BUY Exercise of conversion of derivative security	$10,368 $3.24 p/Share	3,200 Added 37.09%	5,428 Common Stock
Jan 27 2021	SELL Open market or private sale	$96,030 $32.01 p/Share	3,000 Reduced 57.38%	2,228 Common Stock

Maged Shenouda

Chief Financial Officer

New York, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RLMD shares.

Notify only if

Value

Insider Trading

Get notified when an Relmada Therapeutics, Inc. insider buys or sells RLMD shares.

Notify only if

Operation

Value

Type

News

Receive news related to RELMADA THERAPEUTICS, INC.

Track Activities on RLMD

Account